Race Oncology targets two new cancer markets with RC220’s unique molecular action

• R220’s unique molecular mechanism of action opens major clinical and commercial opportunities
• RAC expanding clinical activities to include Acute Myeloid Leukaemia and non-small cell lung cancer trials
• Continued clinical focus on cardioprotection/anticancer opportunity of RC220 in combination with doxorubicin

Special Report: Race Oncology has discovered the unique molecular mechanism of action for its RC220 therapy, opening two new major potential indications to explore in a clinical setting.

The company has revealed plans to begin two new clinical trials involving Acute Myeloid Leukaemia and non-small cell lung cancer, based on the G4-binding mechanism of action of active ingredient (E,E)-bisantrene in RC220.

The drug has potential to delay or prevent resistance to established tyrosine kinase inhibitors (TKIs), potentially reducing or delaying resistance to the highly effective treatments in patients and extending their therapeutic benefit.

Race Oncology (ASX:RAC) is moving full steam ahead with its pivotal Phase 3 Acute Myeloid Leukemia (AML) trial, which is designed to bridge the gap between RC110 to RC220 and provide a rapid, low-cost pathway to regulatory approval of RC220.

As part of the program, RAC will support a low-cost, investigator sponsored Phase 1b/2 trial to identify the optimal combination of RC220 with current standard-of-care AML treatments in the near future.

RAC CEO Dr Daniel Tillet is hosting an online webinar to discuss the new clinical programs and answer investor questions on Tuesday, November 18, 2025.

Registrations can be found here.

Compelling clinical opportunity

At the same time, RAC is in the advanced planning stages for a clinical trial assessing RC220 in non-small cell lung cancer, while maintaining a clinical focus on the cardioprotection/anticancer opportunity of RC220.

There will be no changes to the ongoing Phase 1a/b trial assessing RC220 in combination with the anthracycline doxorubicin, where Race aims to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

RAC managing director and CEO Dr Daniel Tillett said translating RC220’s mechanism of action into tangible clinical programs was an exciting milestone for the company.

“The opportunity to use RC220 to delay, or even prevent, TKI resistance across a range of cancers is a compelling opportunity,” he said.

“The scale of the opportunity is enormous, with more than US$10 billion of EGFRm TKIs sold every year for lung cancer alone.

“I want to especially thank the Race Oncology preclinical and clinical teams for their extraordinary effort in moving from the initial discovery of the mechanism of action of (E,E)-bisantrene to a full clinical trial program in lung cancer in under 9 months.”

Race Oncology has submitted the trial protocol and related documentation to Human Ethics, but the new programs will remain on hold until the company obtains sufficient funding.

With $11.3 million already in the bank, RAC expects the exercise of piggyback options expiring May 29, 2026, to enable all clinical activities to be fully funded.

This article was developed in collaboration with Race Oncology, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.